

# HVC KYOTO 2017

## Don't miss out on the upcoming innovations in Healthcare!

We welcome you to join **HVC KYOTO 2017**, a platform to support new innovations coming out from technology startups and universities seeking to reach global market. We welcome companies, investors and supporters in Healthcare business searching for new technology and business seeds. Please come and join the excitement in the beautiful city of Kyoto!

### ◆ HVC KYOTO 2017: Conference Summary

Event Name	HVC KYOTO 2017 (The First Healthcare Venture Conference KYOTO)
Date	Friday, August 4 <sup>th</sup> 2017 10:00-15:30
Venue	Kyoto Research Park (2 <sup>nd</sup> floor of Building 4 in West Area)
Who we welcome	Companies, investors and supporters searching for new technology & business in Healthcare Business
Admission	FREE
Capacity	100 Participants (Registration open until July 28 <sup>th</sup> )
Registration	WEB Registration through <a href="#">KRP-WEEK Registration page</a>
Inquiries	Makoto Shida HVC KYOTO organizing team, Kyoto Research Park Corp. TEL: 075-315-9040 e-mail: <a href="mailto:hvckyoto@krp.co.jp">hvckyoto@krp.co.jp</a>

**KRP-WEEK**  
PRE EVENT 7.24 MON, 7.28 FRI, 7.29 SAT  
**7.31** MON **8.6** SUN



### ◆ HVC KYOTO 2017: Conference Program (tentative as of July 18th)

Main Venue: Room1 (Exhibition booths are at Room 2&Foyer) ※all sessions provided in English

09:30~	Registration
10:00~10:05	<b>Opening Note</b>
10:05~10:30	Session1 <b>Potentials of Boston/Cambridge Area for Healthcare Startups</b> <b>Ms. Elizabeth Steele:</b> Senior Director, Economic Development & Global Affairs, Massachusetts Biotechnology Council
10:30~10:45	Session2 <b>Introduction of KYOTO-SPARK: New Drug Discovery Acceleration Program</b> <b>Dr. Tomoyoshi Koyanagi:</b> Associate Professor, Medical Science & Business Liaison Organization, Graduate School of Medicine at Kyoto University
10:45~11:00	<b>Coffee Break</b>
11:00~13:00	Session 3 <b>Innovative Startup Presentations (10 startups)</b> Please see back page for details
13:00~14:00	<b>Lunch Break &amp; Networking</b> at Exhibition booths
14:00~14:30	Session 4 <b>Introduction of SPARK Berlin</b> <b>Prof. Craig Garner:</b> Founder, SPARK Berlin
14:30~15:30	Session 5 <b>Open Innovation Strategy of Global Healthcare Companies:</b> <b>Johnson &amp; Johnson INNOVATION, Takeda Pharmaceutical Company Ltd.</b>
15:30	<b>Closing</b>

<b>Organizers</b>	Japan External Trade Organization (JETRO), Kyoto Prefecture, Kyoto City, Kyoto Industry-Academia-Government Cooperative Organization, Kyoto Research Park Corp.
<b>Co-Organizers</b>	Kyoto University Medical Science and Business Liaison Organization (KUMBL)
<b>Support</b>	近畿経済産業局、京都商工会議所、大阪商工会議所、神戸商工会議所、(公財)都市活力研究所、NPO法人「関西健康・医療学術連絡会」、関西健康・医療創生会議、合同会社SARR

#### Partners

Platinum

**Johnson & Johnson INNOVATION**



Silver



JSR Life Sciences



バイエル薬品株式会社

MIYAKO CAPITAL



100年つづく「のれん」を一緒に。  
Future Venture Capital

# Innovative Startup Presentations

Presenters (As of July 4<sup>th</sup> Company name in alphabetical orders)

<b>Title</b>	<b>AFI Corporation's business</b>	<b>Speaker</b>	AFI Corporation Takaharu Enjoji, CEO
<b>Speaker Profile</b>			
ENJOJI worked at SHIGEMATSU WORKS of an industrial respirator manufacturer as a chief engineer of R&D division for ten years. He founded FILTECHNO JAPAN in 2007 specialized to dielectrophoresis (DEP) technology, a sort of electrostatic phenomena, and developed flow-separation tools of microorganisms for university and food/beverage industry researchers. In 2013, He founded AFI Corporation and started to develop the rapid microorganisms detection equipment "ELESTA" based on DEP technologies. He assumed CEO in 2014. He holds a PhD in engineering from Tokyo Metropolitan University in 2012. His specialty is microbiology and DEP.			
<b>Title</b>	<b>Drug Discovery based on Glycan Technology</b>	<b>Speaker</b>	GlyTech, Inc. Hirofumi Ochiai, Manager, Research & Development
<b>Speaker Profile</b>			
Hirofumi Ochiai received his Ph.D. from Kyoto University in 2005. After postdoctoral research at Konan University and the University of Maryland School of Medicine, he moved to Otsuka Chemical Co., Ltd. in 2009. In 2013 he joined GlyTech, Inc., where he has been working as a researcher.			
<b>Title</b>	<b>HACARUS challenging the healthcare industry with the unique AI</b>	<b>Speaker</b>	Hacarus Inc. Kenshin Fujiwara, CEO
<b>Speaker Profile</b>			
Kenshin is the CEO at Hacarus, a healthcare technology startup based in Kyoto, Japan. Previously he worked on the Playstation for Sony Computer Entertainment and was part of a startup derived from the Israeli Military. In the past 15 years, Kenshin co-founded several tech startups with two successful exits. The first startup was acquired by a Japanese public company, and the second startup was sold to a US company. Since 2010, Kenshin has been living in Kyoto rediscovering the strengths of intellectual property owned by local universities and the richness of food culture that Kyoto has to offer. Born in Shiga in 1976, Kenshin holds a Computer Science degree from California State University.			
<b>Title</b>	<b>Cardiac cells derived from iPS cells</b>	<b>Speaker</b>	iHeart Japan Corporation Kenji Kakuta, President & CEO
<b>Speaker Profile</b>			
Prior to iHeart Japan Corporation, he worked for investment company, being in charge of venture capital investment in bio-tech companies.			
<b>Title</b>	<b>A new class of anti-DNA viral drugs</b>	<b>Speaker</b>	KinoPharma, Inc. Masafumi Kuroishi, CEO
<b>Speaker Profile</b>			
He founded Watervein Partners in 2002, and incubated and invested in technology created in academia in the field of biopharma. He was appointed CEO at Kinopharma in 2011 and since then has been working on the development of new concept antiviral drugs.			
<b>Title</b>	<b>High quality iPS cell-derived cardiomyocytes which are differentiated under xeno-free and cytokine free conditions</b>	<b>Speaker</b>	Myoridge Co. Ltd. Naohiro Makita, President
<b>Speaker Profile</b>			
He belongs to Kyoto University Graduate School of Engineering. He supported research in a laboratory of Itsunari Minami at iCeMS, Kyoto University. He established Myoridge Co. Ltd. with Shinichi Sueta who is a director, CTO in order to make use of research results of Minami for innovative drug development.			
<b>Title</b>	<b>Regcell Co., Ltd. - Generate innovative cell therapy by controlling the immune system</b>	<b>Speaker</b>	RegCell Naoto Matsuda, CEO
<b>Speaker Profile</b>			
He started his career with Fujifilm Corporation after obtaining Master's degree in Organic Science at Waseda University. In 2015, he joined iPS Portal Inc. as Vice President, Manager and Executive Secretariat. He then became CEO of Regcell Co. Ltd. when the company was founded in Jan. 2016.			
<b>Title</b>	<b>Introduction of innovative binder selection technology contributing to the discovery of small molecule drugs.</b>	<b>Speaker</b>	SEEDSUPPLY Inc. Naoki Tarui, CEO
<b>Speaker Profile</b>			
He had been engaged in drug discovery for Takeda over the past 20 years. His technological efforts especially for constructing chemical library and for following systematic screening successively identified dozens of drug seeds. One of the candidates, named Takecab, finally launched to the market in 2015.			
<b>Title</b>	<b>Autism spectrum disorder drug discovery and its related business</b>	<b>Speaker</b>	SkySea Pharmaceutical Inc. Yuji Kogami, President & CEO
<b>Speaker Profile</b>			
He started his career with Toyo Brewery Co., Ltd. in 1986. When the company merged with Asahi Kasei Co., Ltd., he joined the synthetic laboratory at Asahi Kasei Co. Ltd. In 2006, he founded PRISM Bio Lab Co., Ltd. with 2 other members and led the company's R&D activity. He also founded D.D.P. Co. Ltd (2010) and became the President & CEO before establishing SkySea Pharmaceutical Inc. in 2015.			
<b>Title</b>	<b>Development of endometrial microbiome testing for reproductive health</b>	<b>Speaker</b>	Varinos Inc. Yoko Nagai, Co-founder & CTO
<b>Speaker Profile</b>			
In 2014, she joined Illumina KK as a sequencing specialist to consulting and encourage human genome research. In 2017, she founded Varinos Inc., a biotechnology company focused on clinical genomic test development and service, with Dr. Sakuraba, a clinical specialist of Illumina KK. Their aim is to provide genome medicine to everyone.			